Accelerate Brain Cancer Cure held its 10th Annual Scientific Meeting from September 28-30th in Sausalito, California. Leaders on the frontier of cancer research, along with top funders, gathered to share translational research developments, foster collaboration and identify new opportunities for the coming year. "We bring together the best and the brightest in cancer research with the hopes of inspiring innovative thinking to accelerate science and make new therapies a reality for patients," said Max Wallace, CEO of ABC2. "Our annual meeting has an excellent track record of seeding promising collaborations across institutional lines."
The meeting was attended by preeminent scientists and clinicians, as well as patients, industry and government officials representing more than 25 institutions, including: UCLA, Genentech, Duke University, Amgen, Fred Hutchinson Cancer Research Center, Google, UCSD, Tocagen, Celgene, The Chordoma Foundation, Harvard/Dana Farber, UCSF, The National Brain Tumor Society, Johns Hopkins, MD Anderson Cancer Center, Novartis, The V Foundation, Quintiles Innovation, Agios, The Ludwig Institute for Cancer Research and others.
The presentations focused on innovations in translational research, including: multiple genetic pathways that lead to brain cancer, therapeutic potential of targeting the IDH1 gene, and immune therapy approaches to battling the disease.
Click here for the 2011 Annual Scientific Meeting agenda.
